New anticoagulants in the management of venous thromboembolism in women

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective diagnosis and treatment are important in optimizing clinical outcomes in patients with venous thromboembolism (VTE), and anticoagulants are the mainstay of treatment. Traditionally, anticoagulant therapy involves parenteral anticoagulants, overlapping with and followed by oral vitamin K antagonists. Recently, direct oral anticoagulants (DOACs), including the Factor Xa inhibitors rivaroxaban, apixaban and edoxaban, and the direct thrombin inhibitor dabigatran etexilate, have been developed to address limitations associated with traditional anticoagulant therapy. DOACs have recently been approved for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE). Successful phase III trials have demonstrated their efficacy for the treatment of DVT and PE, with a potentially improved safety profile. Recent evidence suggests that women bleed more compared to men when treated with DOACs for VTE without differences in treatment efficacy. Future clinical trials should include outcomes stratified by sex, and should investigate the clinical impact of this sex-related safety difference.

Original languageEnglish
Pages (from-to)S5-S7
JournalThrombosis Research
Volume135
Issue numberS1
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

Venous Thromboembolism
Anticoagulants
Pulmonary Embolism
Venous Thrombosis
Therapeutics
Safety
Antithrombins
Vitamin K
Clinical Trials

Keywords

  • Deep vein thrombosis (DVT)
  • Direct oral anticoagulants (DOACs)
  • Pulmonary embolism (PE)
  • Venous thromboembolism (VTE)

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

New anticoagulants in the management of venous thromboembolism in women. / Piovella, Franco; Irina Iosub, Diana.

In: Thrombosis Research, Vol. 135, No. S1, 01.02.2015, p. S5-S7.

Research output: Contribution to journalArticle

@article{f0eb9fb2c8e040b88ba16643bfa53ff9,
title = "New anticoagulants in the management of venous thromboembolism in women",
abstract = "Objective diagnosis and treatment are important in optimizing clinical outcomes in patients with venous thromboembolism (VTE), and anticoagulants are the mainstay of treatment. Traditionally, anticoagulant therapy involves parenteral anticoagulants, overlapping with and followed by oral vitamin K antagonists. Recently, direct oral anticoagulants (DOACs), including the Factor Xa inhibitors rivaroxaban, apixaban and edoxaban, and the direct thrombin inhibitor dabigatran etexilate, have been developed to address limitations associated with traditional anticoagulant therapy. DOACs have recently been approved for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE). Successful phase III trials have demonstrated their efficacy for the treatment of DVT and PE, with a potentially improved safety profile. Recent evidence suggests that women bleed more compared to men when treated with DOACs for VTE without differences in treatment efficacy. Future clinical trials should include outcomes stratified by sex, and should investigate the clinical impact of this sex-related safety difference.",
keywords = "Deep vein thrombosis (DVT), Direct oral anticoagulants (DOACs), Pulmonary embolism (PE), Venous thromboembolism (VTE)",
author = "Franco Piovella and {Irina Iosub}, Diana",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/S0049-3848(15)50431-3",
language = "English",
volume = "135",
pages = "S5--S7",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "S1",

}

TY - JOUR

T1 - New anticoagulants in the management of venous thromboembolism in women

AU - Piovella, Franco

AU - Irina Iosub, Diana

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Objective diagnosis and treatment are important in optimizing clinical outcomes in patients with venous thromboembolism (VTE), and anticoagulants are the mainstay of treatment. Traditionally, anticoagulant therapy involves parenteral anticoagulants, overlapping with and followed by oral vitamin K antagonists. Recently, direct oral anticoagulants (DOACs), including the Factor Xa inhibitors rivaroxaban, apixaban and edoxaban, and the direct thrombin inhibitor dabigatran etexilate, have been developed to address limitations associated with traditional anticoagulant therapy. DOACs have recently been approved for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE). Successful phase III trials have demonstrated their efficacy for the treatment of DVT and PE, with a potentially improved safety profile. Recent evidence suggests that women bleed more compared to men when treated with DOACs for VTE without differences in treatment efficacy. Future clinical trials should include outcomes stratified by sex, and should investigate the clinical impact of this sex-related safety difference.

AB - Objective diagnosis and treatment are important in optimizing clinical outcomes in patients with venous thromboembolism (VTE), and anticoagulants are the mainstay of treatment. Traditionally, anticoagulant therapy involves parenteral anticoagulants, overlapping with and followed by oral vitamin K antagonists. Recently, direct oral anticoagulants (DOACs), including the Factor Xa inhibitors rivaroxaban, apixaban and edoxaban, and the direct thrombin inhibitor dabigatran etexilate, have been developed to address limitations associated with traditional anticoagulant therapy. DOACs have recently been approved for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE). Successful phase III trials have demonstrated their efficacy for the treatment of DVT and PE, with a potentially improved safety profile. Recent evidence suggests that women bleed more compared to men when treated with DOACs for VTE without differences in treatment efficacy. Future clinical trials should include outcomes stratified by sex, and should investigate the clinical impact of this sex-related safety difference.

KW - Deep vein thrombosis (DVT)

KW - Direct oral anticoagulants (DOACs)

KW - Pulmonary embolism (PE)

KW - Venous thromboembolism (VTE)

UR - http://www.scopus.com/inward/record.url?scp=84922989579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922989579&partnerID=8YFLogxK

U2 - 10.1016/S0049-3848(15)50431-3

DO - 10.1016/S0049-3848(15)50431-3

M3 - Article

C2 - 25903537

AN - SCOPUS:84922989579

VL - 135

SP - S5-S7

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - S1

ER -